NEW YORK (GenomeWeb News) – Agilent Technologies reported after the close of the market on Wednesday that revenues for its fiscal third quarter shrank 4 percent year over year, although the Diagnostics and Genomics segment saw revenues grow 54 percent.

The company brought in a total of $1.65 billion for the three months ended July 31, down from $1.72 billion a year ago, but narrowly edging out the average Wall Street estimate of $1.64 billion.

Orders were down 4 percent year over year to $1.60 billion from $1.66 billion.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.